Rating Change
Leerink Partners analysts reiterated a Outperform rating on Keros Therapeutics, Inc. (NASDAQ:KROS) on August 04, 2026.
reiterateNASDAQ:KROS
Leerink Partners Reiterates Outperform Rating on Keros Therapeutics, Inc. (KROS)
Rating Change Leerink Partners analysts reiterated a Outperform rating on Keros Therapeutics, Inc. (NASDAQ:KROS) on August 04, 2026. Market Context Keros Therapeutics, Inc.
Market Context
Keros Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $10.11 with a market capitalization of $878.9M.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Keros Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Keros Therapeutics, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Leerink Partners | Outperform | N/A |
| Mar 05, 2026 | Wells Fargo | Overweight | N/A |
| Nov 28, 2025 | B of A Securities | Neutral | N/A |
| Nov 12, 2025 | Oppenheimer | Outperform | N/A |
| Nov 11, 2025 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View KROS Stock Page
Frequently Asked Questions
What does a Outperform rating mean for KROS?
A Outperform rating from Leerink Partners reflects the analyst's outlook on Keros Therapeutics, Inc. (NASDAQ:KROS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KROS forecast page.